AlzeCure Pharma AB appointed Martin Jönsson as the company’s new CEO. Former CEO Johan Sandin, who is also one of the founders of AlzeCure Pharma, remains at the company as chief scientific officer.

Jönsson comes most recently from a senior position at Ferring Pharmaceuticals in the United States, where for the past five years, among other things, he was business area director for a number of therapy areas. He has extensive experience from various positions at both Ferring Pharmaceuticals and Roche, where he worked with business development, in- and out-licensing of pharmaceuticals, marketing and sales, and alliance management.

“I am happy to welcome Martin as the new CEO of AlzeCure. With over 20 years’ experience in the global pharmaceutical industry, and senior positions in several different areas, I’m convinced that Martin is the right person to work intensively with our out-licensing business and continue to develop the broad portfolio of candidate drugs that Johan and the team at AlzeCure have built up,” says Thomas Pollare, chairman of the board of AlzeCure Pharma.

AlzeCure executives say the company is ready to enter the clinical stage and aims to have two candidate drugs in clinic trials by the end of 2020; as the company enters a new phase, it is a central and natural step to further strengthen the company’s leadership with expertise and experience from the business side.

“At the same time, being the company’s CEO since its inception, Johan has played a vital role in establishing AlzeCure and leading the company through critical phases, in terms of research as well as financially and organizationally, including the listing on Nasdaq First North Premier Growth Market just over a year ago,” Pollare says. “I look forward to continue working with Johan when he, at his own request, enters another operational role in the company, with the responsibility for AlzeCure’s clinical and preclinical research.”

AlzeCure is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease.